AbbVie and Genmab announced that Epkinly (tucatinib? or Epkinly—company‑reported agent) did not prolong overall survival in a Phase 3 study for diffuse large B‑cell lymphoma (DLBCL). The randomized trial enrolled patients who had received at least one prior therapy; the failure to improve OS is the primary readout the programs were targeting. The negative Phase 3 outcome removes a near‑term approval pathway for the drug in DLBCL and will force both companies to reassess development strategy and potential label claims. Sponsors are evaluating subgroup and secondary endpoint data to determine follow‑on plans and investor guidance. Regulatory filings, commercialization plans and partner expectations will be updated once full datasets are released.